Signaling to cardiac hypertrophy: Insights from human and mouse RASopathies

Molecular Medicine

Volumn 18, Issue 6, 2012, Pages 938-947

  Sala, Valentina ^a   Gallo, Simona ^a   Leo, Christian ^a   Gatti, Stefano ^a   Gelb, Bruce D ^b   Crepaldi, Tiziana ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RAF PROTEIN; RAS PROTEIN; VEMURAFENIB;

ANTINEOPLASTIC ACTIVITY; COSTELLO SYNDROME; DEVELOPMENTAL DISORDER; DRUG EFFICACY; DRUG SAFETY; GENE MUTATION; GENETIC MANIPULATION; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; LEOPARD SYNDROME; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MOUSE; NONHUMAN; NOONAN SYNDROME; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN CROSS LINKING; RASOPATHY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CARDIOMEGALY; CARDIOMYOPATHY, HYPERTROPHIC; HUMANS; MICE; MUTATION; NEOPLASMS; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 84865226993     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2011.00512     Document Type: Review

References (128)

1. Shih TY, Papageorge AG, Stokes PE, Weeks MO, Scolnick EM. (1980) Guanine nucleotide-binding and autophosphorylating activities associated with the p21src protein of Harvey murine sarcoma virus. Nature. 287:686-91.
2. Raman M, Chen W, Cobb MH. (2007) Differential regulation and properties of MAPKs. Oncogene. 26:3100-12.
3. Yoon S, Seger R. (2006) The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors. 24:21-44.
4. Hill JA, Olson EN. (2008) Mechanisms of disease: cardiac plasticity. New. Engl. J. Med. 358:1370-80.
5. Takai Y, Sasaki T, Matozaki T. (2001) Small GTP-binding proteins. Physiol. Rev. 81:153-208.
6. Xu GF, et al. (1990) The Neurofibromatosis Type-1 gene encodes a protein related to GAP. Cell. 62:599-608.
7. Tartaglia M, et al. (2001) Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat. Genet. 29:465-8.
8. Kontaridis MI, Swanson KD, David FS, Barford D, Neel BG. (2006) PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects. J. Biol. Chem. 281:6785-92.
9. Pandit B, et al. (2007) Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat. Genet. 39:1007-12.
10. Lin AE, et al. (2011) Clinical, pathological, and molecular analyses of cardiovascular abnormalities in Costello Syndrome: a Ras/MAPK pathway syndrome. Am. J. Med. Genet. A. 155A:486-507.
11. Gripp KW, et al. (2006) HRAS mutation analysis in Costello syndrome: genotype and phenotype correlation. Am. J. Med. Genet. A. 140A:1-7.
12. Sarkozy A, Digilio MC, Dallapiccola B. (2008) Leopard syndrome. Orphanet J. Rare Dis. 3:13.
13. Gripp KW, et al. (2007) Further delineation of the phenotype resulting from BRAF or MEK1 germline mutations helps differentiate cardiofacio-cutaneous syndrome from Costello syndrome. Am. J. Med. Genet. A. 143A:1472-80.
14. Niihori T, et al. (2006) Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat. Genet. 38:294-6.
15. Rodriguez-Viciana P. et al. (2006) Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science. 311:1287-90.
16. Cirstea IC, et al. (2010) A restricted spectrum of NRAS mutations causes Noonan syndrome. Nat. Genet. 42:27-9.
17. Martinelli S, et al. (2010) Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype. Am. J. Hum. Genet. 87:250-7.
18. Roberts AE, et al. (2007) Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat. Genet. 39:70-4.
19. Tartaglia M, et al. (2002) PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am. J. Hum. Genet. 70:1555-63.
20. Rose BA, Force T, Wang YB. (2010) Mitogen activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. Physiol. Rev. 90:1507-46.
21. Yutzey KE, Colbert M, Robbins J (2005) Ras-related signaling pathways in valve development: ebb and flow. Physiol. 20:390-7.
22. Rochais F, Mesbah K, Kelly RG (2009) Signaling pathways controlling second heart field development. Circ. Res. 104:933-42.
23. Snarr BS, Kern CB, Wessels A (2008) Origin and fate of cardiac mesenchyme. Dev. Dyn. 237:2804-19.
24. Lin AE, et al. (2009) Prenatal features of Costello syndrome: ultrasonographic findings and atrial tachycardia. Prenatal Diag. 29:682-90.
25. Smith LP, Podraza J, Proud VK. (2009) Polyhydramnios, fetal overgrowth, and macrocephaly: prenatal ultrasound findings of Costello syndrome. Am. J. Med. Genet. A. 149A: 779-84.
26. Dorn GW II, Brown JH. (1999) Gq signaling in cardiac adaptation and maladaptation. Trends Cardiovasc. Med. 9:26-34.
27. Heineke J, Molkentin JD. (2006) Regulation of cardiac hypertrophy by intracellular signaling pathways. Nat. Rev. Mol. Cell. Biol. 7:589-600.
28. Xiao L, et al. (2001) MEK1/2-ERK1/2 mediates alpha(1)-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes. J. Mol. Cell. Cardiol. 33:779-87.
29. Dwyer JP, et al. (2008) Myocardial gene expression associated with genetic cardiac hypertrophy in the absence of hypertension. Hypertens. Res. 31:941-55.
30. Muslin AJ. (2008) MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets. Clin. Sci. 115:203-18.
31. Onan D, Pipolo L, Yang E, Hannan RD, Thomas WG. (2004) Urotensin II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases. Mol. Endocrinol. 18:2344-54.
32. Samarel AM et al. (2001) Src and multiple MAP kinase activation in cardiac hypertrophy and congestive heart failure under chronic pressureoverload: comparison with acute mechanical stretch. J. Mol. Cell. Cardiol. 33:1637-48.
33. Wang YB. (2007) Mitogen-activated protein kinases in heart development and diseases. Circulation. 116:1413-23.
34. Olson EN, Schneider MD. (2003) Sizing up the heart: development redux in disease. Genes Dev. 17:1937-56.
35. Blaxall BC, Tschannen-Moran BM, Milano CA, Koch WJ. (2003) Differential gene expression and genomic patient stratification following left ventricular assist device support. J. Am. Coll. Cardiol. 41:1096-06.
36. Lowes BD, et al. (2002) Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. New Engl. J. Med. 346:1357-65.
37. Esposito G, et al. (2002) Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation. 105:85-92.
38. Frey N, Katus HA, Olson EN, Hill JA. (2004) Hypertrophy of the heart: a new therapeutic target? Circulation. 109:1580-9.
39. Fuller SJ, Finn SG, Downward J, Sugden PH. (1998) Stimulation of gene expression in neonatal rat ventricular myocytes by Ras is mediated by Ral guanine nucleotide dissociation stimulator (Ral.GDS) and phosphatidylinositol 3-kinase in addition to Raf. Biochem. J. 335:241-6.
40. Thorburn A, et al. (1993) Hras-dependent pathways can activate morphological and genetic-markers of cardiac-muscle cell hypertrophy. J. Biol. Chem. 268:2244-9.
41. Kai H, et al. (1998) Expression of proto-oncogenes and gene mutation of sarcomeric proteins in patients with hypertrophic cardiomyopathy. Circ. Res. 83:594-601.
42. Hunter JJ, Tanaka N, Rockman HA, Ross J, Chien KR. (1995) Ventricular expression of A Mlc-2V-Ras fusion gene induces cardiac-hypertrophy and selective diastolic dysfunction in transgenic mice. J. Biol. Chem. 270:23173-8.
43. Schuhmacher AJ, et al. (2008) A mouse model for Costello syndrome reveals an Ang II-mediated hypertensive condition. J. Clin. Invest. 118:2169-79.
44. Santoriello C, et al. (2009) Expression of H-RASV12 in a zebrafish model of Costello syndrome causes cellular senescence in adult proliferating cells. Dis. Model Mech. 2:56-67.
45. Leo C, et al. (2011) Activated Met signalling in the developing mouse heart leads to cardiac disease. Plos One. 6:e14675.
46. Zhang SS, et al. (2003) The role of the Grb2-p38 MAPK signaling pathway in cardiac hypertrophy and fibrosis. J. Clin. Invest. 111:833-41.
47. Chen PC, et al. (2010) Activation of multiple signaling pathways causes developmental defects in mice with a Noonan syndrome-associated Sos1 mutation. J. Clin. Invest. 120:4353-65.
48. Araki T, et al. (2004) Mouse model of Noonan syndrome reveals cell typeand gene dosage-dependent effects of Ptpn11 mutation. Nat. Med. 10:849-57.
49. Marin TM, et al. (2011) Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. J. Clin. Invest. 121:1026-43.
50. Oudit GY, Penninger JM. (2009) Cardiac regulation by phosphoinositide 3-kinases and PTEN. Cardiovasc. Res. 82:250-60.
51. Yano N, et al. (2008) Temporally controlled over-expression of cardiac-specific PI3K alpha induces enhanced myocardial contractility-a new transgenic model. Am. J. Physiol. Heart Circ. Physiol. 295:H1690-4.
52. McMullen JR, et al. (2003) Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc. Natl. Acad. Sci. U. S. A. 100:12355-60.
53. McMullen JR, et al. (2007) Protective effects of exercise and phosphoinositide 3-kinase(p110 alpha) si3naling in dilated and hypertrophic cardiomyopathy. Proc. Natl. Acad. Sci. U. S. A. 104:612-7.
54. Ruan HM, et al. (2009) Inducible and cardiac specific PTEN inactivation protects ischemia/reperfusion injury. J. Mol. Cell. Cardiol. 46:193-200.
55. Shiojima I, et al. (2005) Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J. Clin. Invest. 115:2108-18.
56. Harris IS, et al. (2004) Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload. Circulation. 110:718-23.
57. Klein M et al. (2008) Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling. Circulation. 118:2081-90.
58. Kobayashi T, et al. (2010) Molecular and clinical analysis of RAF1 in Noonan syndrome and related disorders: dephosphorylation of serine 259 as the essential mechanism for mutant activation. Hum. Mutat. 31:284-94.
59. Wu X. (2011) MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1L613V mutation. J. Clin. Invest. 121:1009-25.
60. Urosevic J, et al. (2011) Constitutive activation of B-Raf in the mouse germ line provides a model for human cardio-facio-cutaneous syndrome. Proc. Natl. Acad. Sci. U. S. A. 108:5015-20.
61. Allanson JE et al. (2011) Cardio-Facio-Cutaneous syndrome: does genotype predict phenotype? Am. J. Med. Genet. C. Semin. Med. Genet. 157:129-35.
62. Clerk A, Aggeli IKS, Stathopoulou K, Sugden PH. (2006) Peptide growth factors signal differentially through protein kinase C to extracellular signal-regulated kinases in neonatal cardiomyocytes. Cell. Signal. 18:225-35.
63. Kennedy RA, Kemp TJ, Sugden PH, Clerk A. (2006) Using U0126 to dissect the role of the extracellular signal-regulated kinase 1/2 (ERK1/2) cascade in the regulation of gene expression by endothelin-1 in cardiac myocytes. J. Mol. Cell. Cardiol. 41:236-47.
64. Sanada S, et al. (2003) Long-acting Ca2+ blockers prevent myocardial remodeling induced by chronic NO inhibition in rats. Hypertension. 41:963-7.
65. Yue TL, et al. (2000) Extracellular signal-regulated kinase plays an essential role in hypertrophic agonists, endothelin-1 and phenylephrine-induced cardiomyocyte hypertrophy. J. Biol. Chem. 275: 37895-901.
66. Armstrong SC. (2004) Protein kinase activation and myocardial ischemia/reperfusion injury. Cardiovasc. Res. 61:427-36.
67. Takeishi Y, et al. (2002) Activation of mitogen-activated protein kinases and p90 ribosomal S6 kinase in failing human hearts with dilated cardiomyopathy. Cardiovasc. Res. 53:131-7.
68. Huebert RC, et al. (2004) Identification and regulation of Sprouty1, a negative inhibitor of the ERK cascade, in the human heart. Physiol. Genomics. 18:284-9.
69. Bueno OF, et al. (2001) The dual-specificity phosphatase MKP-1 limits the cardiac hypertrophic response in vitro and in vivo. Circ. Res. 88:88-96.
70. Purcell NH, et al. (2007) Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo. Proc. Natl. Acad. Sci. U. S. A. 104:14074-9.
71. Luttrell DK, Luttrell LM. (2003) Signaling in time and space: G protein-coupled receptors and mitogen-activated protein kinases. Assay Drug Dev. Techn. 1:327-38.
72. Owens DM, Keyse SM. (2007) Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene. 26:3203-13.
73. Lorenz K, Schmitt JP, Schmitteckert EM, Lohse MJ. (2009) A new type of ERK1/2 autophosphorylation causes cardiac hypertrophy. Nat. Med. 15:75-83.
74. Bueno OF, et al. (2000) The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. Embo. J. 19:6341-50.
75. Slupsky JR, et al. (1999) Binding of G beta gamma subunits to cRaf1 downregulates G-proteincoupled receptor signalling. Curr. Biol. 9:971-4.
76. Metrich M, et al. (2008) Epac mediates beta-adrenergic receptor-induced cardiomyocyte hypertrophy. Circ. Res. 102:959-65.
77. Morel E, et al. (2005) cAMP-binding protein Epac induces cardiomyocyte hypertrophy. Circ. Res. 97:1296-304.
78. Ponsioen B, et al. (2004) Detecting cAMP-induced Epac activation by fluorescence resonance energy transfer: Epac as a novel cAMP indicator. Embo. Rep. 5:1176-80.
79. de Rooij J, et al. (1998) Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature. 396:474-77.
80. Kawasaki H, et al. (1998) A family of cAMP-binding proteins that directly activate Rap1. Science. 282:2275-9.
81. Holz GG, Kang G, Harbeck M, Roe MW, Chepurny OG. (2006) Cell physiology of cAMP sensor Epac. J. Physiol. 577:5-15.
82. Schmidt M, Sand C, Jakobs KH, Michel MC, Weernink PA. (2007) Epac and the cardiovascular system. Curr. Opin. Pharmacol. 7:193-200.
83. Barki-Harrington L, Perrino C, Rockman HA. (2004) Network integration of the adrenergic system in cardiac hypertrophy. Cardiovasc. Res. 63:391-402.
84. Salazar NC, Chen J, Rockman HA. (2007) Cardiac GPCRs: GPCR signaling in healthy and failing hearts. Biochim. Biophys. Acta. 1768:1006-18.
85. Kuster GM, et al. (2005) Alpha-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes is mediated via thioredoxin-1-sensitive oxidative modification of thiols on Ras. Circulation. 111:1192-8.
86. Aoki H, Richmond M, Izumo S, Sadoshima J. (2000) Specific role of the extracellular signal-regulated kinase pathway in angiotensin II-induced cardiac hypertrophy in vitro. Biochem. J. 347:275-84.
87. Cullingford TE, et al. (2008) Temporal regulation of expression of immediate early and second phase transcripts by endothelin-1 in cardiomyocytes. Genome Biol. 9:R32.
88. Wright CD, et al. (2008) Nuclear alpha 1-adrenergic receptors signal activated ERK localization to caveolae in adult cardiac myocytes. Circ. Res. 103:992-1000.
89. Torsoni AS, Constancio SS, Nadruz W, Hanks SK, Franchini KG. (2003) Focal adhesion kinase is activated and mediates the early hypertrophic response to stretch in cardiac myocytes. Circ. Res. 93:140-7.
90. Nadruz W, Corat MAF, Marin TM, Pereira GAG, Franchini KG. (2005) Focal adhesion kinase mediates MEF2 and c-Jun activation by stretch: role in the activation of the cardiac hypertrophic genetic program. Cardiovasc. Res. 68:87-97.
91. Passier R, et al. (2000) CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo. J. Clin. Invest. 105:1395-406.
92. McKinsey TA, Zhang CL, Olson EN. (2002) MEF2: a calcium-dependent regulator of cell division, differentiation and death. Trends Biochem. Sci. 27:40-7.
93. Miyata S, Minobe W, Bristow MR, Leinwand LA. (2000) Myosin heavy chain isoform expression in the failing and nonfailing human heart. Circ. Res. 86:386-90.
94. Abraham WT, et al. (2002) Coordinate changes in myosin heavy chain isoform gene expression are selectively associated with alterations in dilated cardiomyopathy phenotype. Mol. Med. 8:750-60.
95. Braunwald E, Bristow MR. (2000) Congestive heart failure: fifty years of progress. Circulation. 102:14-23.
96. Mitchell S, et al. (2006) Distinct gene expression profiles in adult mouse heart following targeted MAP kinase activation. Physiol. Genomics. 25:50-9.
97. Ruan HM, et al. (2007) Gi alpha 1-mediated cardiac electrophysiological remodeling and arrhythmia in hypertrophic cardiomyopathy. Circulation. 116:596-605.
98. Chen J, et al. (1998) Selective requirement of myosin light chain 2v in embryonic heart function. J. Biol. Chem. 273:1252-6.
99. Ho PD, et al. (2001) Ras reduces L-type calcium channel current in cardiac myocytes - corrective effects of L-channels and SERCA2 on [Ca2+](i) regulation and cell morphology. Circ. Res. 88:63-9.
100. Zheng MZ, et al. (2004) Sarcoplasmic reticulum calcium defect in Ras-induced hypertrophic cardiomyopathy heart. Am. J. Physiol. Heart Circ. Physiol. 286: H424-33.
101. Frey N, McKinsey TA, Olson EN. (2000) Decoding calcium signals involved in cardiac growth and function. Nat. Med. 6:1221-7.
102. Crabtree GR, Olson EN. (2002) NFAT signaling: choreographing the social lives of cells. Cell. 109: S67-79.
103. Molkentin JD, et al. (1998) A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 93:215-28.
104. Chaudhary A, et al. (2000) Phosphatidylinositol3-kinase regulates Raf1 through Pak phosphorylation of serine 338. Curr. Biol. 10:551-4.
105. Grimminger F, Schermuly RT, Ghofrani HA. (2010) Targeting non-malignant disorders with tyrosine kinase inhibitors. Nat. Rev. Drug. Discov. 9:956-70.
106. Tuveson DA, et al. (2004) Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell. 5:375-87.
107. Lei L et al. (2008) Hypoxia-inducible factordependent degeneration, failure, and malignant transformation of the heart in the absence of the von Hippel-Lindau protein. Mol. Cell. Biol. 28:3790-803.
108. Comoglio PM, Giordano S, Trusolino L. (2008) Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat. Rev. Drug. Discov. 7:504-16.
109. Grossmann KS. (2011) The tyrosine phosphatase Shp2 in development and cancer. Adv. Cancer Res. 106:53-89.
110. Young A, et al. (2009) Ras signaling and therapies. Adv Cancer Res. 102:1-17.
111. Gutkind JS, Offermanns S. (2009) A new Gqinitiated MAPK signaling pathway in the heart. Dev. Cell. 16:163-4.
112. Flaherty KT, et al. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. New Engl. J. Med. 363:809-19.
113. Garrett JT, Arteaga CL. (2011) Resistance to HER2-directed antibodies and tyrosine kinase inhibitors. Cancer Biol. Ther. 11:793-800.
114. Poulikakos PI, Solit DB. (2011) Resistance to MEK inhibitors: should we co-target upstream? Sci. Signal. 4:pe16.
115. Solit DB, Rosen N. (2011) Resistance to BRAF inhibition in melanomas. New Engl. J. Med. 364:772-4.
116. Bueno OF, Molkentin JD. (2002) Involvement of extracellular signal-regulated kinases 1/2 in cardiac hypertrophy and cell death. Circ. Res. 91:776-81.
117. Sugden PH & Clerk A. (2006) Oxidative stress and growth-regulating intracellular signaling pathways in cardiac myocytes. Antioxid. Redox Signal. 8:2111-24.
118. Lips DJ, et al. (2004) MEK1-ERK2 signaling pathway protects myocardium from ischemic injury in vivo. Circulation. 109:1938-41.
119. Yamaguchi O, et al. (2004) Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis. J. Clin. Invest. 114:937-43.
120. Le Mellay V, Troppmair J, Benz R, Rapp UR. (2002) Negative regulation of mitochondrial VDAC channels by C-Raf kinase. BMC Cell Biol. 3:14.
121. O'Neill E. (2011) Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1. Science. 306:2267-70.
122. Rapp UR, Rennefahrt U, Troppmair J. (2004) Bcl-2 proteins: master switches at the intersection of death signaling and the survival control by Raf kinases. Biochim Biophys Acta 1644:149-58.
123. Tian S, et al. (2006) Interaction and stabilization of X-linked inhibitor of apoptosis by Raf-1 protein kinase. Int. J. Oncol. 29:861-7.
124. Cox AD, Der CJ. (2003) The dark side of Ras: regulation of apoptosis. Oncogene 22:8999-9006.
125. Park IH, Kim JY, Jung JI, Han JY. (2010) Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations. Invest. New Drugs. 28:791-9.
126. Perchellet JP, et al. (2009) Novel synthetic inhibitors of 3-hydroxy-3-methylglutarylcoenzyme A (HMG-CoA) reductase activity that inhibit tumor cell proliferation and are structurally unrelated to existing statins. Int. J. Mol. Med. 24:633-43.
127. Patel R, et al. (2001) Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation. 104:317-24.
128. Senthil V, et al. (2005) Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circ. Res. 97:285-92.